deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT04681105

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies

Sponsor: City of Hope Medical Center

Conditions Recurrent Acute Leukemia Recurrent B Acute Lymphoblastic Leukemia Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recurrent Hairy Cell Leukemia Recurrent Hematologic Malignancy Recurrent Hodgkin Lymphoma Recurrent T Acute Lymphoblastic Leukemia Refractory Acute Leukemia Refractory B Acute Lymphoblastic Leukemia Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive Refractory Hairy Cell Leukemia Refractory Hematologic Malignancy Refractory Hodgkin Lymphoma Refractory T Acute Lymphoblastic Leukemia Systemic Mastocytosis
Interventions Acetaminophen Dexamethasone Diphenhydramine Flotetuzumab Ibuprofen Ranitidine
Updated 10 times since 2021 Last updated: Jan 27, 2026 Started: Nov 18, 2020 Primary completion: Aug 5, 2025 Completion: Aug 5, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Recurrent Acute Leukemia and Recurrent B Acute Lymphoblastic Leukemia, this trial is completed. The trial is conducted by City of Hope Medical Center and has accumulated 10 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshotRecruiting~Feb 2021 – ~Dec 2021 · 10 months · monthly snapshotRecruiting~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshotRecruiting~Dec 2022 – ~Oct 2023 · 10 months · monthly snapshotRecruiting~Oct 2023 – ~Jan 2024 · 3 months · monthly snapshotActive Not Recruiting~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshotActive Not Recruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotActive Not Recruiting~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshotActive Not Recruiting~Feb 2025 – ~Feb 2026 · 12 months · monthly snapshotActive Not Recruiting~Feb 2026 – present · 5 months · monthly snapshotCompleted

Change History

10 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Feb 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Jan 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 5 earlier versions

  1. Oct 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Dec 2022 — Oct 2023 [monthly]

    Recruiting PHASE1

  3. Dec 2021 — Dec 2022 [monthly]

    Recruiting PHASE1

  4. Feb 2021 — Dec 2021 [monthly]

    Recruiting PHASE1

  5. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1

    First recorded

Nov 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • City of Hope Medical Center
  • National Cancer Institute (NCI)
Data source: City of Hope Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations